- Conditions
- Dry Eye Disease
- Interventions
- Propylene glycol-based eye drops
- Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Kansas City, Missouri • Norfolk, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 937–960
of 2,634
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Interventions
- UGN-301, UGN-201, Gemcitabine
- Drug
- Lead sponsor
- UroGen Pharma Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more
- Conditions
- HIV Infections, Sexually Transmitted Diseases
- Interventions
- PrEPmate, Dot Diary
- Other · Device
- Lead sponsor
- Public Health Foundation Enterprises, Inc.
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Miami, Florida
- Conditions
- Muscular Dystrophies
- Interventions
- GSK3439171A, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Radiation therapy, Goserelin, Cyclophosphamide, Tecemotide (L-BLP25)
- Radiation · Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Cystic Fibrosis-related Diabetes
- Interventions
- Insulin, Continuous glucose monitor (CGM)
- Drug · Device
- Lead sponsor
- Jagdeesh Ullal
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Positron-Emission Tomography, Metastatic Solid Tumors
- Interventions
- ⁸⁹Zr-Df-IAB22M2C
- Drug
- Lead sponsor
- ImaginAb, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more
- Conditions
- Psoriasis
- Interventions
- Humira®, BI 695501
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Encinitas, California • Los Angeles, California + 17 more
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- filgrastim, recombinant interferon alfa, busulfan, cyclophosphamide, melphalan, pamidronate disodium, thalidomide, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2018
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Duarte, California
- Conditions
- Graft-versus-host Disease
- Interventions
- Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Ruxolitinib
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Pemphigus
- Interventions
- Sirolimus (formerly known as Rapamycin)
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Advanced Cancer
- Interventions
- FLT-PET
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Ga-68 labeled HBED-CC PSMA, Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT), Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)
- Drug · Device
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Neoplasm, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenocarcinoma Ovary, Serous Adenocarcinoma of Ovary, Serous Adenocarcinoma of Primary Peritoneum, Primary Peritoneal Carcinoma, High Grade Serous Adenocarcinoma
- Interventions
- AVB-001 (Dose Escalation Phase), AVB-001 (Dose Expansion Phase)
- Drug
- Lead sponsor
- Avenge Bio, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 5
- States / cities
- Bethesda, Maryland • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Colonoscopy Preparation
- Interventions
- PEG-ELS current standard of care, PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Novi, Michigan • Southfield, Michigan • Warren, Michigan
- Conditions
- Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease
- Interventions
- Deferoxamine, Deferasirox, HIDA
- Drug · Radiation
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Myelodysplastic Syndromes (MDS)
- Interventions
- Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
- Combination Product
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland + 9 more
- Conditions
- Primary Heart Transplant, Heart Transplantation, Heart Transplant
- Interventions
- bortezomib, plasmapheresis
- Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • San Francisco, California • New Haven, Connecticut + 9 more
- Conditions
- ALK-positive Non-small Cell Lung Cancer
- Interventions
- Ceritinib, Stereotactic ablative body radiation
- Drug · Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hypertension in Pregnancy
- Interventions
- Labetalol or Nifedipine
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 14 Years to 89 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Prostate Cancer, High Risk
- Interventions
- 68Ga-PSMA
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy
- Interventions
- MK-1167, Diltiazem
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Graft Vs Host Disease, Graft-versus-host-disease
- Interventions
- Belimumab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- High-grade Glioma, Solid Tumor, Unspecified, Child
- Interventions
- LAM561
- Drug
- Lead sponsor
- Laminar Pharmaceuticals
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Miami, Florida • Edison, New Jersey